scholarly journals Is Europe facing an opioid crisis like the US? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018

2021 ◽  
pp. 1-29
Author(s):  
Mimi Pierce ◽  
Jan van Amsterdam ◽  
Gerard A. Kalkman ◽  
Arnt Schellekens ◽  
Wim van den Brink
Author(s):  
Daniel J Hemel ◽  
Lisa Larrimore Ouellette

Abstract The US has recently—and belatedly—come to recognize opioid addiction as a public health crisis. What has gone mostly unrecognized is the degree to which this crisis is intertwined with US intellectual property law and related elements of US innovation policy. Innovation institutions—the legal arrangements that structure incentives for production and allocation of knowledge goods—encouraged the development and commercialization of addictive painkillers, restricted access to opioid antidotes, and (perhaps most importantly) failed to facilitate investments in alternative, nonaddictive treatments for chronic pain. Although innovation policy does not bear all the blame for the opioid wave that has washed over communities across the country, innovation institutions are bound up in the ongoing epidemic to a degree that so far has gone underappreciated. This article examines the proliferation of opioid use and abuse through the lens of innovation policy, and it envisions ways in which innovation institutions could help to contain the crisis. Along the way, it seeks to derive broader lessons for innovation policy scholarship as well as recommendations for institutional reform. The opioid crisis challenges the conventional understanding of IP law as a trade-off between allocative efficiency and dynamic efficiency; it highlights the potentially pernicious role of IP protection for addictive and habit-forming products; and it exposes deep flaws in the structure of federal subsidies for and regulation of prescription drugs. It also draws attention to the political and cultural factors that contribute to innovation policy failures. Ultimately, the opioid crisis underscores both the urgency and the limits of institutional change in the innovation policy domain.


2021 ◽  
Vol 108 (Supplement_1) ◽  

Abstract   Presenting Author Email: [email protected] Research Question Opioid misuse is a major health epidemic. Surveys in the US have shown that over 130 patients die daily due to opioid related drug overdose with 10.3 million patients misused prescription opioids in 2018. This is the first study in the UK to explore the magnitude of the opioid crisis in our country. The opioid crisis was identified first in the US after life expectancy reduced dramatically in 2015. One of the main reasons attributed to this was the increase in the number of overdoses and suicides, both linked with the use of opioid drugs. Between 1999 and 2017 the number of deaths from opioid overdoses increased almost six fold. The 2019 National Survey on Drug use and Health in the US showed that 10.3 million patients misused prescription opioids in 2018 and 2 million patients with an opioid use disorder. Factors contributing to opioid dependence were identified as the use of modified release formulations, the use of repeat opioid prescriptions and the treatment of acute pain. Background and Aim The aim of the study is to explore the magnitude of the opioid crisis in the UK, by identifying risk factors for persistent opioid use following major general surgical intervention. Design Phase 1 of the OPiOiD study is a national retrospective audit. We are aiming to identify risk factors for persistent opioid use in patients undergoing major general surgical interventions. Specifically we will be assessing the number of patients given a duration or point of review when opioids should be stopped and whether any written information has been given to these patients on discharge regarding safe use of opioids and de-prescribing advice. 23 hospitals across the UK have registered so far. Data are collected using the electronic discharge summaries send to the GPs and copies given to patients. Phase 2 of the study will be to proceed with a national observational study with the aim to develop strategies to promote safe and effective management of acute pain. Team and infrastructure The East Midlands Surgical Academic Network (EMSAN) leads the study, supervised by Dr Roger Knaggs, Associate Professor School of Pharmacy University of Nottingham, Dr Nicholas Levy, Department of Anaesthesia and peri-operative Medicine West Suffolk NHS Foundation Trust and Professor Dileep Lobo, Nottingham Digestive Diseases Centre National Institute for Health Research.


2021 ◽  
Vol 14 (2) ◽  
pp. 145
Author(s):  
Othman Al Musaimi ◽  
Danah Al Shaer ◽  
Fernando Albericio ◽  
Beatriz de la Torre

2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.


2020 ◽  
pp. 1-3 ◽  
Author(s):  
Nubia Muñoz

It is too early to know which will be the final death toll from the Covid-19 or SARS-CoV-2 virus epidemy in Latin America since the epidemy is still active and we will not know when it will end. The curve for new infections and deaths has not reached yet a peak (Figure 1). In addition, we know little about the epidemiology of this new virus. The daily litany of the number of people infected with the number of admissions to hospitals and intensive care units and the number of deaths guides health authorities to plan health services and politicians to gauge the degree of confinement necessary to control the transmission of the virus, but it says little about the magnitude of the problem if we do not relate it to the population at risk. At the end of the pandemic, we will be able to estimate age-standardized death rates for the different countries, but until then the crude death rates will provide a first glance or snapshot of the death toll and impact of the pandemic from March to May 2020. These rates are well below those estimated in other countries in Europe and North America: Belgium (82.6), Spain (58.0), the United Kingdom (57.5), Italy (55.0), France (42.9), Sweden (41.4), and the US (30.7). (Johns Hopkins CSSE, May 30, 2020). However, in the European countries and the US the number of deaths has reached a peak, while this is not the case in Latin American countries. (Figure 1). It should be taken into account that the above rates are crude and therefore, some of the differences could be due to the fact that European countries have a larger proportion of the population over 70 years of age in whom higher mortality rates have been reported.


1987 ◽  
Vol 19 (3) ◽  
pp. 313-321 ◽  
Author(s):  
Gary S. Grubb

SummaryIn January 1985, a Gallup poll sponsored by the American College of Obstetrics and Gynecologists reported that 76% of the US women sampled thought that there were substantial risks with using the pill, 31% thought the pill caused cancer and 64% thought the risk of childbearing was equal to or less than that in taking the pill. To assess the perceptions of the pill's safety internationally, a survey of 100–150 urban, middle-class women aged 18–45 years was conducted in each of eight countries in the developing world. There were striking similarities in perceptions of the pill's health effects between countries: (1) taking the pill is considered to have substantial health risks by 50–75% and is thought to be more hazardous than childbearing by over 40% of respondents except those in the African samples; (2) women who had used the pill are as unaware as those who had not of possible serious cardiovascular adverse effects; (3) the protective effects of the pill are virtually unknown; (4) the greatest inconsistency with scientific evidence concerns the risks of sterility and birth defects attributed to pill use. With information from this survey, family planning programmes can rectify almost universal misperceptions of the pill's safety when counselling new and continuing pill users.


2014 ◽  
Vol 15 ◽  
pp. 91-99 ◽  
Author(s):  
Anca Munteanu ◽  
Angela Filip ◽  
Andreea Pece

2018 ◽  
Vol 21 ◽  
pp. S2
Author(s):  
W Lo-Ciganic ◽  
WF Gellad ◽  
L Zhou ◽  
JM Donohue ◽  
A Roubal ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document